PharmaCielo Struggles To Complete Financing, Extends Closing To March
It appears that PharmaCielo (TSXV: PCLO) is having a difficult time raising funds for its operations. The firm this morning
Read more
PharmaCielo
PharmaCielo Looks To Raise $15.0 Million Via 11% Secured Debentures
PharmaCielo (TSXV: PCLO) is returning to the trough for more investor dollars. The firm this morning indicated that it intends
Read more
PharmaCielo Records $0.4 Million In Revenue, $7.2 Million Net Loss In Q2 2021
PharmaCielo Ltd. (TSXV: PCLO) reported today its financial performance for the quarter ending June 30, 2021. The results highlighted a
Read more
PharmaCielo Third Quarter Revenues Crater 97.9%, CEO Forced Out
PharmaCielo Ltd (TSXV: PCLO) this morning filed its third quarter financial results, posting brutal revenues of just $25,913 – a
Read more
PharmaCielo Sees Marc Lustig Appointed As Lead Director, Conducts $10 Million Financing
It appears that PharmaCielo Ltd (TSXV: PCLO) has effectively locked in a new lead director. The company announced yesterday evening
Read more
Khiron Receives National Strategic Project Status From Colombian Government
This morning Khiron Life Sciences Corp (TSXV: KHRN) announced they received the status of National Interest Strategic Project by the Government
Read more
Stifel Reinitiates Coverage On Eight Cannabis Operators
Earlier this week, Stifel released a new report on cannabis operations, focused predominantly on US-based multi state operators, while re-initiating
Read more
PharmaCielo Conducts $4.0 Million Bought Deal Financing
PharmaCielo Ltd (TSXV: PCLO) is the latest firm to announce a bought deal financing. The firm announced this morning that
Read more
Pharmacielo Latest Target of Hindenburg Research
Pharmacielo Ltd (TSXV: PCLO) is the latest target of short sellers Hindenburg Research, with Hindenburg alleging that the company has
Read more
PharmaCielo Enters Supply Agreement With Xphyto Therapeutics
PharmaCieolo Ltd. (TSXV: PCLO) has announced a supply agreement with Xphyto Therapeutics Corp (CSE: XPHY). The three year agreement will
Read more